We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Genetic Technologies Ltd | NASDAQ:GENE | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.1196 | 5.30% | 2.3742 | 2.35 | 2.39 | 2.49 | 2.31 | 2.49 | 29,334 | 20:21:14 |
Executive Chairman of GTG, Dr Paul Kasian said, “the University of Cambridge has one of Europe’s leading academic departments of population health sciences and cancer genetic epidemiology. GTG is proud to be associated with these two prestigious research institutes for this project.
This collaborative study provides two major benefits for GTG:
(i) engagement and collaboration with high profile cancer genetics researchers in the U.S.A. and Europe who are at the forefront of risk assessment research; and
(ii) the resulting data has the potential to inform the design of future pipeline products for GTG
The specific terms and conditions of the Agreement are confidential but at a high level, GTG will supply novel SNP-based genotyping for a clinical research study, through its CLIA laboratory facility, Phenogen Sciences Inc, on a fee for service basis.”
GTG will be responsible for the development and validation of the new genetic assay, noting the fundamental technology is similar to the existing GTG developed BREVAGenplus breast cancer test and will fit synergistically into the Company’s existing Melbourne-based laboratory infrastructure and processes. Importantly, if the first phase of the study is successful, several other major genetics centres in the U.S. have expressed an interest in joining the study.
Dr Kasian said, “this Agreement represents another milestone for GTG as it seeks to expand its genetic testing product pipeline and become a key player in the genetic cancer risk assessment landscape in Australia, the USA and in Asia”.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul Kasian Jason Wong (USA)
Chairman and Acting CEO Media and Investor Relations
Genetic Technologies Limited Blueprint Life Science Group
+61 3 8412 7000 +1 (415) 375 3340, Ext. 4
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor StatementAny statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
1 Year Genetic Technologies Chart |
1 Month Genetic Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions